New bladder cancer drug enters human testing
NCT ID NCT07222488
Summary
This study is testing a new medicine called MK-3120 for people with high-risk bladder cancer that is still in the lining of the bladder and hasn't spread to the muscle. The medicine is placed directly into the bladder. The main goals are to see if the treatment is safe and if people can tolerate it well after their initial tumor removal surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Akershus Universitetssykehus ( Site 0091)
RECRUITINGLorenskog, Akershus, 1478, Norway
Contact Phone: •••-•••-••••
-
Ankara University Health Practice and Research Hospitals ( Site 0132)
RECRUITINGAnkara, 06620, Turkey (Türkiye)
Contact Phone: •••-•••-••••
-
CHU de Quebec - Hopital de l'Enfant-Jesus ( Site 0011)
RECRUITINGQuébec, Quebec, G1J 1Z4, Canada
Contact Phone: •••-•••-••••
-
Carolina Urologic Research Center ( Site 0006)
RECRUITINGMyrtle Beach, South Carolina, 29572, United States
Contact Phone: •••-•••-••••
-
European Interbalkan Medical Center ( Site 0051)
RECRUITINGThessaloniki, 570 01, Greece
Contact Phone: •••-•••-••••
-
Hospital Universitario 12 de Octubre ( Site 0112)
RECRUITINGMadrid, Madrid, Comunidad de, 28041, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitario Virgen de la Victoria ( Site 0111)
RECRUITINGMálaga, Andalusia, 29010, Spain
Contact Phone: •••-•••-••••
-
Michael G Oefelein Clinical Trials ( Site 0005)
RECRUITINGBakersfield, California, 93301, United States
Contact Phone: •••-•••-••••
-
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 0081)
RECRUITINGAmsterdam, North Holland, 1066 CX, Netherlands
Contact Phone: •••-•••-••••
-
Rabin Medical Center ( Site 0062)
RECRUITINGPetah Tikva, 4941492, Israel
Contact Phone: •••-•••-••••
-
UZ Gent ( Site 0031)
RECRUITINGGhent, Oost-Vlaanderen, 9000, Belgium
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.